spacer
home > ebr > autumn 2006 > eurobio: meeting europe's potential in the life sciences
PAY PER VIEW SERVICE

 

Dear guest!

article: EuroBiO: Meeting Europe's Potential in the Life Sciences
format: Adobe Acrobat PDF file
cost: £

spacer

 
News and Press Releases

Novartis Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya® (fingolimod) Dosing Regimen Patent

Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC’s decision with the US Supreme Court.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement